NEO News NeoGenomics Revises Upward its Quarter
Post# of 29840
Posted On: 09/26/2013 7:41:13 AM
NEO News
NeoGenomics Revises Upward its Quarter 3 2013 Guidance
FT. MYERS, Fla., Sept. 26, 2013 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it was revising upward its previously issued guidance for Quarter 3, 2013. The Company now expects revenue of approximately $16.6 - $16.9 million and earnings per share of $0.01 - $0.02 in the third quarter. The Company had originally guided to revenue of $15.8 - $16.4 million and earnings per share of $0.00 - $0.01 on July 31, 2013.
Doug VanOort, the Company's Chairman and CEO, commented, "We experienced strong year-over-year revenue growth in July and August, and our rate of growth has continued to accelerate in September. This growth is broad-based, and is the result of a variety of growth initiatives we have made over the last eighteen months, including, but not limited to, increasing sales force productivity and various new product launches. We are scheduled to release our full third quarter financial results on October 23, 2013."
The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.
Interested parties can also access investor relations material from Hawk Associates at http://www.hawkassociates.com or neogenomics@hawk.com and from Zack's Investment Research at http://www.zacks.com or scr@zacks.com.
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.
SOURCE NeoGenomics, Inc.
Copyright 2013 PR Newswire
NeoGenomics Revises Upward its Quarter 3 2013 Guidance
FT. MYERS, Fla., Sept. 26, 2013 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it was revising upward its previously issued guidance for Quarter 3, 2013. The Company now expects revenue of approximately $16.6 - $16.9 million and earnings per share of $0.01 - $0.02 in the third quarter. The Company had originally guided to revenue of $15.8 - $16.4 million and earnings per share of $0.00 - $0.01 on July 31, 2013.
Doug VanOort, the Company's Chairman and CEO, commented, "We experienced strong year-over-year revenue growth in July and August, and our rate of growth has continued to accelerate in September. This growth is broad-based, and is the result of a variety of growth initiatives we have made over the last eighteen months, including, but not limited to, increasing sales force productivity and various new product launches. We are scheduled to release our full third quarter financial results on October 23, 2013."
The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.
Interested parties can also access investor relations material from Hawk Associates at http://www.hawkassociates.com or neogenomics@hawk.com and from Zack's Investment Research at http://www.zacks.com or scr@zacks.com.
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.
SOURCE NeoGenomics, Inc.
Copyright 2013 PR Newswire
(0)
(0)